Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae.

Chaubey VP, Pitout JD, Dalton B, Ross T, Church DL, Gregson DB, Laupland KB.

BMC Res Notes. 2010 Apr 27;3:116. doi: 10.1186/1756-0500-3-116.

3.

Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters.

Cheng WL, Hsueh PR, Lee CC, Li CW, Li MJ, Chang CM, Lee NY, Ko WC.

J Microbiol Immunol Infect. 2016 Apr;49(2):208-15. doi: 10.1016/j.jmii.2014.05.003. Epub 2014 Jul 26.

5.

Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.

Han SB, Jung SW, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, Cho B, Kang JH, Kim HK, Park YJ.

Microb Drug Resist. 2015 Apr;21(2):244-51. doi: 10.1089/mdr.2014.0092. Epub 2014 Nov 14.

PMID:
25398058
6.

Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2015 May 1;60(9):1319-25. doi: 10.1093/cid/civ003. Epub 2015 Jan 13. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

7.

Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.

Chopra T, Marchaim D, Johnson PC, Chalana IK, Tamam Z, Mohammed M, Alkatib S, Tansek R, Chaudhry K, Zhao JJ, Pogue JM, Kaye KS.

Am J Infect Control. 2015 Jul 1;43(7):719-23. doi: 10.1016/j.ajic.2015.02.030. Epub 2015 Apr 29.

PMID:
25934068
8.

Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.

Zaoutis TE, Goyal M, Chu JH, Coffin SE, Bell LM, Nachamkin I, McGowan KL, Bilker WB, Lautenbach E.

Pediatrics. 2005 Apr;115(4):942-9.

PMID:
15805368
9.

Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.

Lee CI, Lee NY, Yan JJ, Lee HC, Ko NY, Chang CM, Wu CJ, Chen PL, Wang LR, Ko WC.

J Microbiol Immunol Infect. 2009 Aug;42(4):303-9.

PMID:
19949753
10.

Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study.

Thom KA, Schweizer ML, Osih RB, McGregor JC, Furuno JP, Perencevich EN, Harris AD.

BMC Infect Dis. 2008 Sep 15;8:116. doi: 10.1186/1471-2334-8-116.

11.

Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.

Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC.

Antimicrob Agents Chemother. 2012 Jun;56(6):2888-93. doi: 10.1128/AAC.06301-11. Epub 2012 Mar 19.

12.

Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia.

Ku NS, Kim YC, Kim MH, Song JE, Oh DH, Ahn JY, Kim SB, Kim HW, Jeong SJ, Han SH, Kim CO, Song YG, Kim JM, Choi JY.

Arch Gerontol Geriatr. 2014 Jan-Feb;58(1):105-9. doi: 10.1016/j.archger.2013.07.002. Epub 2013 Aug 8.

PMID:
23988261
13.

Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study.

Song KH, Jeon JH, Park WB, Park SW, Kim HB, Oh MD, Lee HS, Kim NJ, Choe KW.

BMC Infect Dis. 2009 Apr 12;9:41. doi: 10.1186/1471-2334-9-41.

14.

Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.

Tsui K, Wong SS, Lin LC, Tsai CR, Chen LC, Huang CH.

J Microbiol Immunol Infect. 2012 Jun;45(3):193-9. doi: 10.1016/j.jmii.2011.11.003. Epub 2012 May 12.

15.

Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.

Kang CI, Chung DR, Ko KS, Peck KR, Song JH; Korean Network for Study of Infectious Diseases.

Ann Hematol. 2012 Jan;91(1):115-21. doi: 10.1007/s00277-011-1247-7. Epub 2011 May 10.

PMID:
21556875
16.

Clinical and microbiologic characteristics of adult patients with recurrent bacteraemia caused by extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.

Lee CH, Su LH, Chen FJ, Tang YF, Chien CC, Liu JW.

Clin Microbiol Infect. 2015 Dec;21(12):1105.e1-8. doi: 10.1016/j.cmi.2015.07.025. Epub 2015 Aug 10.

17.

Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs.

Maslikowska JA, Walker SA, Elligsen M, Mittmann N, Palmay L, Daneman N, Simor A.

J Hosp Infect. 2016 Jan;92(1):33-41. doi: 10.1016/j.jhin.2015.10.001. Epub 2015 Oct 22.

PMID:
26597637
19.

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.

Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC.

Antimicrob Agents Chemother. 2002 May;46(5):1481-91.

20.

Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.

Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, Yoo JH, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS.

Ann Hematol. 2013 Apr;92(4):533-41. doi: 10.1007/s00277-012-1631-y. Epub 2012 Nov 17.

PMID:
23161391

Supplemental Content

Support Center